Metoprolol succinate

CAS No. 98418-47-4

Metoprolol succinate ( —— )

Catalog No. M16894 CAS No. 98418-47-4

A selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 49 In Stock
50MG 72 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Metoprolol succinate
  • Note
    Research use only, not for human use.
  • Brief Description
    A selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension.
  • Description
    A selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension.Hypertension Approved
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    Adrenergic Receptor
  • Recptor
    β1-adrenergicreceptor
  • Research Area
    Cardiovascular Disease
  • Indication
    Hypertension

Chemical Information

  • CAS Number
    98418-47-4
  • Formula Weight
    652.82
  • Molecular Formula
    C34H56N2O10
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.C(CC(=O)O)C(=O)O
  • Chemical Name
    Butanedioic acid, compd. with 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol (1:2)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • 3,4,5-Trimethoxyphen...

    ——

  • MK-4618

    A potent and selective full β3 adrenergic receptor agonist with EC50 of 1.1 nM; displays no activity for β1 and β2 receptors (EC50>20 uM).

  • Olodaterol

    A potent, selective long-acting β2 adrenoceptor agonist with EC50 of 1.4 nM for hβ2; shows >250 fold selectivity over hβ1; exerts a bronchodilatory efficacy over 24 h in dogs and guinea pigs in the absence of systemic pharmacodynamic effects.COPDPhase 3 Clinical